Drs Jacob Sands and Jared Weiss discuss subtypes; ongoing clinical trials; durable, ongoing responses to therapy; and the potential for using the word "cure" in the treatment of small cell lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Immunotherapy and Lung Cancer Treatment https://www.medscape.com/viewarticle/969534

Small Cell Lung Cancer (SCLC) https://emedicine.medscape.com/article/280104-overview

FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer

Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer https://ascopubs.org/doi/10.1200/JCO.2006.06.5821

Study of Trilaciclib and Lurbinectidin https://clinicaltrials.gov/ct2/show/NCT05578326

PL02.03 Lurbinectedin/Doxorubicin Versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial https://www.jto.org/article/S1556-0864(21)02453-9/fulltext

Erythropoiesis-Stimulating Agents in Oncology: A Study-Level Meta-Analysis of Survival and Other Safety Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816662

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) https://clinicaltrials.gov/ct2/show/NCT05361395

Bispecific T-Cell Engager (BiTE) Antibodies https://reference.medscape.com/drugs/bispecific-t-cell-engager-bite-antibodies